Guardant Health, Inc. (GH) shareholders
GHNasdaqServices-Medical LaboratoriesFiscal year ends December 31
$151.70−3.16 (-2.04%)
Close on Nov 13, 2026Market cap $20.36BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
99.8%
134M of 134M shares
Institutional holders
597
158 new, 41 sold out
Net institutional buying
-1M
In Q2 2026
Insider trades, 12 months
1 buys · 141 sales
Net sold $172.85M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Abigail P. Johnson Joint filing with FMR LLC (5.80%) | 7,733,224 | 5.80% | 13G (passive) | Sep 30, 2026 |
| BlackRock, Inc. | 6,895,256 | 5.20% | 13G (passive) amendment | Jun 30, 2026 |
| Vanguard Capital Management | 6,589,394 | 5.02% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of GH | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 7,622,935 | 5.68% | $1.14B | −3,930,824 | 0.02% |
| Price T Rowe Associates Inc /Md/ | 6,514,952 | 4.85% | $977.44M | −508,737 | 0.10% |
| Vanguard Capital Management LLC | 5,755,857 | 4.29% | $863.55M | +131,677 | 0.02% |
| FMR LLC | 5,488,272 | 4.09% | $823.41M | +1,372,191 | 0.04% |
| Vanguard Portfolio Management LLC | 5,445,785 | 4.06% | $817.03M | −392,207 | 0.04% |
| Invesco Ltd. | 4,429,755 | 3.30% | $664.60M | −516,714 | 0.05% |
| Goldman Sachs Group Inc | 3,775,895 | 2.81% | $566.50M | −659,944 | 0.05% |
| Two Sigma Investments, LP | 3,719,301 | 2.77% | $558.01M | −510,230 | 0.40% |
| Capital International Investors | 3,399,604 | 2.53% | $510.04M | −81,714 | 0.11% |
| Deep Track Capital, LP | 3,393,312 | 2.53% | $509.10M | +55,071 | 7.41% |
| Franklin Resources Inc | 3,236,065 | 2.41% | $485.51M | −212,128 | 0.11% |
| Ameriprise Financial Inc | 3,150,897 | 2.35% | $472.78M | +1,736,011 | 0.10% |
| Fuller & Thaler Asset Management, Inc. | 2,629,007 | 1.96% | $394.43M | +78,693 | 1.07% |
| Geode Capital Management, LLC | 2,521,596 | 1.88% | $378.41M | −987,287 | 0.02% |
| Baillie Gifford & Co | 2,284,127 | 1.70% | $342.69M | −1,574,919 | 0.31% |
| State Street Corp | 2,263,504 | 1.69% | $339.62M | −621,116 | 0.01% |
| Federated Hermes, Inc. | 1,999,178 | 1.49% | $299.94M | +111,594 | 0.43% |
| Eventide Asset Management, LLC | 1,957,828 | 1.46% | $293.79M | −404,551 | 3.93% |
| Lord, Abbett & Co. LLC | 1,813,491 | 1.35% | $272.08M | −85,622 | 0.78% |
| Jane Street Group, LLC | 1,783,444 | 1.33% | $267.57M | +1,778,641 | 0.02% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 597 | 134M | 99.8% | 158 / 199 | 179 / 41 | 21M | 22M |
| Q1 2026 | 486 | 135M | 100.0% | 73 / 193 | 159 / 78 | 32M | 19M |
| Q4 2025 | 498 | 134M | 99.7% | 141 / 156 | 149 / 32 | 27M | 16M |
| Q3 2025 | 395 | 123M | 91.7% | 71 / 134 | 132 / 39 | 19M | 21M |
| Q2 2025 | 365 | 125M | 93.3% | 69 / 127 | 116 / 44 | 18M | 13M |
| Q1 2025 | 342 | 120M | 89.6% | 91 / 91 | 110 / 45 | 18M | 17M |
| Q4 2024 | 298 | 120M | 89.1% | 63 / 95 | 90 / 32 | 13M | 21M |
| Q3 2024 | 271 | 128M | 95.1% | 44 / 95 | 76 / 53 | 38M | 18M |
| Q2 2024 | 282 | 118M | 88.0% | 69 / 83 | 92 / 42 | 19M | 16M |
| Q1 2024 | 258 | 117M | 86.9% | 44 / 87 | 85 / 79 | 22M | 21M |
| Q4 2023 | 295 | 116M | 86.5% | 51 / 80 | 117 / 47 | 20M | 15M |
| Q3 2023 | 296 | 111M | 82.8% | 50 / 101 | 88 / 51 | 14M | 14M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
566 funds held GH in Q2 2026, 29% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of GH | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3,999,645 | 2.98% | $600.07M | 0.03% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 2,888,524 | 2.15% | $433.37M | 0.23% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 1,778,489 | 1.33% | $266.83M | 1.81% | Jun 30, 2026 |
| Franklin Dynatech Fund | 1,750,000 | 1.30% | $262.55M | 0.87% | Jun 30, 2026 |
| Fullerthaler Behavioral Small-Cap Growth | 1,729,500 | 1.29% | $259.48M | 4.20% | Jun 30, 2026 |
| Vanguard U.S. Growth Fund | 1,716,540 | 1.28% | $222.62M | 0.47% | May 31, 2026 |
| Vanguard Small-Cap Growth Index Fund | 1,665,905 | 1.24% | $249.94M | 0.53% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,520,630 | 1.13% | $228.14M | 0.23% | Jun 30, 2026 |
| Eventide Gilead Fund | 1,265,290 | 0.94% | $189.83M | 5.52% | Jun 30, 2026 |
| Growth Fund of America | 1,263,832 | 0.94% | $163.91M | 0.05% | May 31, 2026 |
| Invesco Discovery Fund | 1,058,225 | 0.79% | $137.24M | 1.75% | May 31, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 975,588 | 0.73% | $146.37M | 1.23% | Jun 30, 2026 |
| Growth Fund | 968,653 | 0.72% | $145.33M | 0.25% | Jun 30, 2026 |
| Federated Hermes Kaufmann Fund | 916,481 | 0.68% | $148.46M | 3.01% | Jul 31, 2026 |
| Vanguard Explorer Fund | 827,179 | 0.62% | $133.99M | 0.61% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Helmy Eltoukhy | Co-Chief Executive Officer, Director | 1,958,949 | 1.46% | Oct 2, 2026 |
| AmirAli Talasaz | Co-Chief Executive Officer, Director | 1,842,366 | 1.37% | Oct 2, 2026 |
| Robert Parks | Chief Accounting Officer | 0 | – | Nov 12, 2026 |
| Kumud Kalia | Chief Information Officer | 42,773 | 0.03% | Oct 2, 2026 |
| Darya Chudova | Chief Technology Officer | 83,886 | 0.06% | Oct 2, 2026 |
| Terilyn J. Monroe | Chief People Officer | 24,900 | 0.02% | Oct 2, 2026 |
| John G. Saia | Chief Legal Officer | 42,348 | 0.03% | Oct 2, 2026 |
| Chris Freeman | Chief Commercial Officer | 69,647 | 0.05% | Oct 2, 2026 |
| Michael Brian Bell | Chief Financial Officer | 55,182 | 0.04% | Oct 2, 2026 |
| Craig Eagle | Chief Medical Officer | 72,421 | 0.05% | Apr 2, 2026 |
| Alex M. Azar II | Director | 1,031 | 0.00% | Nov 13, 2026 |
| Kevin R. Sayer | Director | 0 | – | Nov 13, 2026 |
| Roberto Mignone | Director | 10,538 | 0.01% | Oct 22, 2026 |
| Medina Manuel Hidalgo | Director | 5,252 | 0.00% | Oct 19, 2026 |
| Musa Tariq | Director | 11,583 | 0.01% | Oct 19, 2026 |
| Steve E. Krognes | Director | 10,177 | 0.01% | Sep 17, 2026 |
| Ian T. Clark | Director | 2,975 | 0.00% | Aug 5, 2026 |
| Myrtle S. Potter | Director | 20,971 | 0.02% | Jun 23, 2026 |
| Vijaya Gadde | Director | 28,517 | 0.02% | Jun 22, 2026 |
| Meghan V. Joyce | Director | 15,386 | 0.01% | Jun 22, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Alex M. Azar II Director | Nov 12, 2026 | Option exercise | +138 | – | – | 1,031 |
| Roberto Mignone Director | Oct 21, 2026 | Option exercise | +264 | – | – | 10,538 |
| Medina Manuel Hidalgo Director | Oct 17, 2026 | Option exercise | +232 | – | – | 5,252 |
| Musa Tariq Director | Oct 16, 2026 | Sale(10b5-1 plan) | −116 | $165.88 | $19.24K | 11,583 |
| Musa Tariq Director | Oct 15, 2026 | Option exercise | +250 | – | – | 11,699 |
| Alex M. Azar II Director | Oct 14, 2026 | Sale(10b5-1 plan) | −69 | $159.89 | $11.03K | 893 |
| Alex M. Azar II Director | Oct 12, 2026 | Option exercise | +137 | – | – | 962 |
| Darya Chudova Chief Technology Officer | Oct 1, 2026 | Tax withholding | −4,320 | $174.75 | $754.92K | 74,348 |
| Darya Chudova Chief Technology Officer | Oct 1, 2026 | Option exercise | +1,701 | – | – | 78,668 |
| Darya Chudova Chief Technology Officer | Oct 1, 2026 | Option exercise | +3,324 | – | – | 76,967 |
| Darya Chudova Chief Technology Officer | Oct 1, 2026 | Option exercise | +1,668 | – | – | 73,643 |
| Darya Chudova Chief Technology Officer | Oct 1, 2026 | Option exercise | +1,340 | – | – | 71,975 |
| Kumud Kalia Chief Information Officer | Oct 1, 2026 | Tax withholding | −3,067 | $174.75 | $535.96K | 42,773 |
| Kumud Kalia Chief Information Officer | Oct 1, 2026 | Option exercise | +1,360 | – | – | 45,840 |
| Kumud Kalia Chief Information Officer | Oct 1, 2026 | Option exercise | +1,995 | – | – | 44,480 |
| Kumud Kalia Chief Information Officer | Oct 1, 2026 | Option exercise | +1,084 | – | – | 42,485 |
| Kumud Kalia Chief Information Officer | Oct 1, 2026 | Option exercise | +1,607 | – | – | 41,401 |
| Chris Freeman Chief Commercial Officer | Oct 1, 2026 | Tax withholding | −3,143 | $174.75 | $549.24K | 69,647 |
| Chris Freeman Chief Commercial Officer | Oct 1, 2026 | Option exercise | +1,292 | – | – | 72,790 |
| Chris Freeman Chief Commercial Officer | Oct 1, 2026 | Option exercise | +2,527 | – | – | 71,498 |
| Chris Freeman Chief Commercial Officer | Oct 1, 2026 | Option exercise | +1,668 | – | – | 68,971 |
| Chris Freeman Chief Commercial Officer | Oct 1, 2026 | Option exercise | +1,929 | – | – | 67,303 |
| AmirAli Talasaz Co-Chief Executive Officer, Director | Oct 1, 2026 | Tax withholding | −17,087 | $174.75 | $2.99M | 1,842,366 |
| AmirAli Talasaz Co-Chief Executive Officer, Director | Oct 1, 2026 | Option exercise | +9,716 | – | – | 1,859,453 |
| AmirAli Talasaz Co-Chief Executive Officer, Director | Oct 1, 2026 | Option exercise | +23,997 | – | – | 1,849,737 |
| Helmy Eltoukhy Co-Chief Executive Officer, Director | Oct 1, 2026 | Tax withholding | −17,087 | $174.75 | $2.99M | 1,958,949 |
| Helmy Eltoukhy Co-Chief Executive Officer, Director | Oct 1, 2026 | Option exercise | +9,716 | – | – | 1,976,036 |
| Helmy Eltoukhy Co-Chief Executive Officer, Director | Oct 1, 2026 | Option exercise | +23,997 | – | – | 1,966,320 |
| John G. Saia Chief Legal Officer | Oct 1, 2026 | Tax withholding | −3,706 | $174.75 | $647.62K | 42,348 |
| John G. Saia Chief Legal Officer | Oct 1, 2026 | Option exercise | +1,496 | – | – | 46,054 |
| John G. Saia Chief Legal Officer | Oct 1, 2026 | Option exercise | +2,925 | – | – | 44,558 |
| John G. Saia Chief Legal Officer | Oct 1, 2026 | Option exercise | +1,668 | – | – | 41,633 |
| John G. Saia Chief Legal Officer | Oct 1, 2026 | Option exercise | +974 | – | – | 39,965 |
| Michael Brian Bell Chief Financial Officer | Oct 1, 2026 | Tax withholding | −3,914 | $174.75 | $683.97K | 55,182 |
| Michael Brian Bell Chief Financial Officer | Oct 1, 2026 | Option exercise | +1,871 | – | – | 59,096 |
| Michael Brian Bell Chief Financial Officer | Oct 1, 2026 | Option exercise | +3,324 | – | – | 57,225 |
| Michael Brian Bell Chief Financial Officer | Oct 1, 2026 | Option exercise | +2,085 | – | – | 53,901 |
| Terilyn J. Monroe Chief People Officer | Oct 1, 2026 | Tax withholding | −2,098 | $174.75 | $366.63K | 24,900 |
| Terilyn J. Monroe Chief People Officer | Oct 1, 2026 | Option exercise | +1,360 | – | – | 26,998 |
| Terilyn J. Monroe Chief People Officer | Oct 1, 2026 | Option exercise | +2,659 | – | – | 25,638 |
| AmirAli Talasaz Co-Chief Executive Officer, Director | Sep 30, 2026 | Tax withholding | −1,428 | $178.36 | $254.70K | 1,825,740 |
| AmirAli Talasaz Co-Chief Executive Officer, Director | Sep 30, 2026 | Option exercise | +2,817 | – | – | 1,827,168 |
| Helmy Eltoukhy Co-Chief Executive Officer, Director | Sep 30, 2026 | Tax withholding | −1,428 | $178.36 | $254.70K | 1,942,323 |
| Helmy Eltoukhy Co-Chief Executive Officer, Director | Sep 30, 2026 | Option exercise | +2,817 | – | – | 1,943,751 |
| Roberto Mignone Director | Sep 21, 2026 | Option exercise | +264 | – | – | 10,274 |
| Medina Manuel Hidalgo Director | Sep 17, 2026 | Option exercise | +232 | – | – | 5,020 |
| Alex M. Azar II Director | Sep 16, 2026 | Sale(10b5-1 plan) | −826 | $175.00 | $144.55K | 825 |
| Steve E. Krognes Director | Sep 16, 2026 | Sale | −3,300 | $175.42 | $578.89K | 10,177 |
| Steve E. Krognes Director | Sep 16, 2026 | Sale | −1,300 | $176.34 | $229.24K | 8,877 |
| Steve E. Krognes Director | Sep 16, 2026 | Sale | −971 | $177.48 | $172.33K | 7,906 |
| Steve E. Krognes Director | Sep 16, 2026 | Sale | −1,103 | $174.46 | $192.43K | 13,477 |
| Musa Tariq Director | Sep 16, 2026 | Sale(10b5-1 plan) | −116 | $175.00 | $20.30K | 11,449 |
| Darya Chudova Chief Technology Officer | Sep 15, 2026 | Sale | −7,738 | $178.00 | $1.38M | 70,635 |
| Musa Tariq Director | Sep 15, 2026 | Option exercise | +249 | – | – | 11,565 |
| Alex M. Azar II Director | Sep 12, 2026 | Option exercise | +1,651 | – | – | 1,651 |
| Kumud Kalia Chief Information Officer | Sep 11, 2026 | Sale | −4,000 | $158.05 | $632.20K | 39,794 |
| Helmy Eltoukhy Co-Chief Executive Officer, Director | Aug 26, 2026 | Other | −25,000 | – | – | 1,970,934 |
| Helmy Eltoukhy Co-Chief Executive Officer, Director | Aug 26, 2026 | Gift | −30,000 | – | – | 1,940,934 |
| Helmy Eltoukhy Co-Chief Executive Officer, Director | Aug 26, 2026 | Other | +25,000 | – | – | 60,000 |
| Roberto Mignone Director | Aug 21, 2026 | Option exercise | +264 | – | – | 10,010 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
7.16%
9M shares short
Days to cover
5.4
At 2M shares a day
Change since last report
-19.2%
From 12M shares
Short volume, 20 days
52.4%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Guardant Health's stock actually held short. Settlement fails (shares not delivered on time) peaked at 6,204 shares on Oct 7, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Musa Tariq Director | Oct 16, 2026 | 116 | $19.24K | Oct 16, 2026 | Restricted Stock Lapse |
| Alex M. Azar II Director | Oct 14, 2026 | 69 | $11.03K | Oct 14, 2026 | Restricted Stock Lapse |
| Steve E. Krognes Director | Sep 16, 2026 | 6,674 | $1.17M | Sep 16, 2026 | Restricted Stock Lapse |
| Alex M. Azar II Director | Sep 16, 2026 | 826 | $144.55K | Sep 16, 2026 | Restricted Stock Lapse |
| Musa Tariq Director | Sep 16, 2026 | 116 | $20.30K | Sep 16, 2026 | Restricted Stock Lapse |
| Darya Chudova Officer | Sep 15, 2026 | 7,738 | $1.38M | Sep 15, 2026 | Restricted Stock Lapse - See Remarks |
| Kumud Kalia Officer | Sep 11, 2026 | 4,000 | $632.19K | Sep 11, 2026 | Restricted Stock Lapse - See Remarks |
| AmirAli Talasaz Officer | Aug 21, 2026 | 37,500 | $6.34M | Aug 21, 2026 | Founder Shares |
| Musa Tariq Director | Aug 17, 2026 | 116 | $18.15K | Aug 17, 2026 | Restricted Stock Lapse |
| Terilyn J. Monroe Officer | Aug 12, 2026 | 46,300 | $7.65M | Aug 12, 2026 | Employee Stock Option Exercise |
| Chris Freeman Officer | Aug 10, 2026 | 63,605 | $10.79M | Aug 10, 2026 | Employee Stock Option Exercise |
| Medina Manuel Hidalgo Director | Aug 5, 2026 | 1,700 | $279.20K | Aug 5, 2026 | Restricted Stock Lapse |
| Meghan V. Joyce Former Affiliate | Aug 5, 2026 | 11,183 | $1.80M | Aug 5, 2026 | Restricted Stock Lapse - See Remarks |
| Ian T. Clark Director | Aug 4, 2026 | 14,180 | $2.25M | Aug 4, 2026 | Restricted Stock Lapse - See Remarks |
| Musa Tariq Director | Jul 16, 2026 | 116 | $18.94K | Jul 16, 2026 | Restricted Stock Lapse |
See a number that looks wrong?